Source:http://linkedlifedata.com/resource/pubmed/id/11858859
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
11-12
|
| pubmed:dateCreated |
2002-2-22
|
| pubmed:abstractText |
We have previously reported that an infection of the lung with BCG-inhibited ovalbumin (OVA)-induced airway eosinophilia. In the current study, we investigated if the intranasal application of heat killed (HK)-BCG or purified protein derivative (PPD) from Mycobacterium tuberculosis had the same effect. For this purpose we treated mice intranasally with either live BCG, HK-BCG or PPD and analyzed if the mice developed airway eosinophilia after immunization and intranasal challenge with OVA. Our results clearly showed that an intranasal vaccination with live and HK-BCG but not PPD, given 4 or 8 weeks prior to allergen airway challenge, resulted in a strong suppression of airway eosinophilia. The inhibition of airway eosinophilia correlated with reduced levels of IL-5 production by T cells from the lymph node of the lungs and a strong reduction in Th2 cell numbers present in the airways of OVA-challenged mice. Furthermore, HK-BCG-induced suppression of airway eosinophilia was strongly reduced in IFN-gamma deficient mice. HK-BCG in contrast to live BCG may also be a promising candidate for a prospective asthma vaccine in humans since negative side effects due to mycobacterial infection can be ruled out.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Allergens,
http://linkedlifedata.com/resource/pubmed/chemical/BCG Vaccine,
http://linkedlifedata.com/resource/pubmed/chemical/Interferon-gamma,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-4,
http://linkedlifedata.com/resource/pubmed/chemical/Ovalbumin,
http://linkedlifedata.com/resource/pubmed/chemical/Tuberculin
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Feb
|
| pubmed:issn |
0264-410X
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:day |
22
|
| pubmed:volume |
20
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1532-40
|
| pubmed:dateRevised |
2008-11-21
|
| pubmed:meshHeading |
pubmed-meshheading:11858859-Administration, Intranasal,
pubmed-meshheading:11858859-Allergens,
pubmed-meshheading:11858859-Animals,
pubmed-meshheading:11858859-Asthma,
pubmed-meshheading:11858859-BCG Vaccine,
pubmed-meshheading:11858859-Bronchoalveolar Lavage Fluid,
pubmed-meshheading:11858859-CD4-Positive T-Lymphocytes,
pubmed-meshheading:11858859-Eosinophilia,
pubmed-meshheading:11858859-Hot Temperature,
pubmed-meshheading:11858859-Immunization,
pubmed-meshheading:11858859-Interferon-gamma,
pubmed-meshheading:11858859-Interleukin-4,
pubmed-meshheading:11858859-Lung,
pubmed-meshheading:11858859-Mice,
pubmed-meshheading:11858859-Mice, Inbred C57BL,
pubmed-meshheading:11858859-Mice, Knockout,
pubmed-meshheading:11858859-Ovalbumin,
pubmed-meshheading:11858859-Th2 Cells,
pubmed-meshheading:11858859-Tuberculin
|
| pubmed:year |
2002
|
| pubmed:articleTitle |
Application of heat killed Mycobacterium bovis-BCG into the lung inhibits the development of allergen-induced Th2 responses.
|
| pubmed:affiliation |
Centre for Infectious Diseases, University of Würzburg, Röntgenring 11, 97070 Würzburg, Germany.
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|